Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Gopalan Narendran"'
Autor:
Rafael Tibúrcio, Gopalan Narendran, Beatriz Barreto-Duarte, Artur T. L. Queiroz, Mariana Araújo-Pereira, Selvaraj Anbalagan, Kaustuv Nayak, Narayanan Ravichandran, Rajasekaran Subramani, Lis R. V. Antonelli, Kumar Satagopan, Komathi Anbalagan, Brian O. Porter, Alan Sher, Soumya Swaminathan, Irini Sereti, Bruno B. Andrade
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
BackgroundTuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) is a clinical aggravation of TB symptoms observed among a fraction of HIV coinfected patients shortly after the start of antiretroviral therapy (ART). Of note, TB
Externí odkaz:
https://doaj.org/article/883059b1d1d449b19ae0435ec13f6847
Autor:
Gopalan Narendran, Keerthana Jyotheeswaran, Thirumaran Senguttuvan, Caian L. Vinhaes, Ramesh K. Santhanakrishnan, Tamizhselvan Manoharan, Anbhalagan Selvaraj, Padmapriyadarsini Chandrasekaran, Pradeep A. Menon, Kannabiran P. Bhavani, Devarajulu Reddy, Ravichandran Narayanan, Balaji Subramanyam, Sekhar Sathyavelu, Raja Krishnaraja, Pownraj Kalirajan, Dhanalakshmi Angamuthu, Stella Mary Susaimuthu, Ranjit R.K. Ganesan, Srikanth P. Tripathy, Soumya Swaminathan, Bruno B. Andrade
Publikováno v:
International Journal of Infectious Diseases, Vol 98, Iss , Pp 261-267 (2020)
Objective: The influence of tuberculosis (TB)-immune reconstitution inflammatory syndrome (IRIS) on TB treatment outcomes and its risk factors were investigated among people with human immunodeficiency virus (HIV) and co-infected with TB. Methods: Ne
Externí odkaz:
https://doaj.org/article/061d764453a448af9209c1040bd14fc3
Autor:
Gopalan Narendran, Deivide Oliveira-de-Souza, Caian L. Vinhaes, Kevan Akrami, Kiyoshi F. Fukutani, Kesavamurthy Banu, Padmapriyadarsini Chandrasekaran, Narayanan Ravichandran, Irini Sereti, Soumya Swaminathan, Bruno B. Andrade
Publikováno v:
BMC Infectious Diseases, Vol 19, Iss 1, Pp 1-5 (2019)
Abstract Background Tuberculosis (TB)-associated Immune reconstitution inflammatory syndrome (TB-IRIS) is an aberrant inflammatory response in TB patients with advanced human immunodeficiency virus coinfection, after antiretroviral therapy commenceme
Externí odkaz:
https://doaj.org/article/d3839150d3a94559a5ab5146cd199b8a
Autor:
Bruce Kirenga, Andrew Nunn, Ewan Tomeny, Jason Madan, Bertel Squire, Laura Rosu, Eve Worrall, Mamo Girma, Vanita Patel, Makwana Mukesh, Malaisamy Muniyandi, Shravan Kumar, Sangeetha Subramani, Saleem Ahmad, Jasper Nidoi, Irina Pirlog, Mariana Macarie, ID Rusen, Gay Bronson, Meera Gurumurthy, Karen Sanders, Sarah Meredith, Wendy Dodds Ben Spittle, Robyn Henry-Cockles, Rachel Bennett, Elisa Giallongo, Danni Maas, Ruth Goodall, Saiam Ahmed, Claire Cook, Katharine Bellenger, Gopalan Narendran, Elena Tudor, Rajesh Solanki, Daniel Meressa, Adamu Bayissa, Anuj Bhatnagar
Publikováno v:
BMJ Open, Vol 10, Iss 12 (2020)
Introduction A December 2019 WHO rapid communication recommended the use of 9-month all-oral regimens for treating multidrug-resistant tuberculosis (MDR-TB). Besides the clinical benefits, they are thought to be less costly than the injectable-contai
Externí odkaz:
https://doaj.org/article/a9fcc9bd4f9a4b70a682711333f0f708
Autor:
Gopalan Narendran, Dhanasekaran Kavitha, Ramesh Karunaianantham, Leonardo Gil-Santana, Jilson L Almeida-Junior, Sirasanambatti Devarajulu Reddy, Marimuthu Makesh Kumar, Haribabu Hemalatha, Nagesh Nalini Jayanthi, Narayanan Ravichandran, Raja Krishnaraja, Angamuthu Prabhakar, Tamizhselvan Manoharan, Lokeswaran Nithyananthan, Gunasundari Arjunan, Mohan Natrajan, Soumya Swaminathan, Bruno B Andrade
Publikováno v:
PLoS ONE, Vol 11, Iss 9, p e0163298 (2016)
BACKGROUND:Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) is an inflammatory phenomenon complicating HIV management in coincidental tuberculosis (TB) infection, upon immune reconstitution driven by antiretro
Externí odkaz:
https://doaj.org/article/8eb05a1171be4c52a37de2f9abd935b3
Autor:
Bruno B Andrade, Amrit Singh, Gopalan Narendran, Melissa E Schechter, Kaustuv Nayak, Sudha Subramanian, Selvaraj Anbalagan, Stig M R Jensen, Brian O Porter, Lis R Antonelli, Katalin A Wilkinson, Robert J Wilkinson, Graeme Meintjes, Helen van der Plas, Dean Follmann, Daniel L Barber, Soumya Swaminathan, Alan Sher, Irini Sereti
Publikováno v:
PLoS Pathogens, Vol 10, Iss 10, p e1004433 (2014)
Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome (TB-IRIS) is an aberrant inflammatory response occurring in a subset of TB-HIV co-infected patients initiating anti-retroviral therapy (ART). Here, we examined monocyte a
Externí odkaz:
https://doaj.org/article/7ae61a2319924ea2a5845cec9905c6e5
Autor:
Gopalan Narendran, Bruno B Andrade, Brian O Porter, Chockalingam Chandrasekhar, Perumal Venkatesan, Pradeep A Menon, Sudha Subramanian, Selvaraj Anbalagan, Kannabiran P Bhavani, Sathiyavelu Sekar, Chandrasekaran Padmapriyadarshini, Satagopan Kumar, Narayanan Ravichandran, Krishnaraj Raja, Kesavamurthy Bhanu, Ayyamperumal Mahilmaran, Lakshmanan Sekar, Alan Sher, Irini Sereti, Soumya Swaminathan
Publikováno v:
PLoS ONE, Vol 8, Iss 5, p e63541 (2013)
The incidence, manifestations, outcome and clinical predictors of paradoxical TB-IRIS in patients with HIV and culture confirmed pulmonary tuberculosis (PTB) in India have not been studied prospectively.HIV+ patients with culture confirmed PTB starte
Externí odkaz:
https://doaj.org/article/7ba4f84d090c44b38c143a6a0d420a3f
Autor:
Gopalan, Narendran1 (AUTHOR) gopalannaren@yahoo.co.in, Senthil, Sumathi2 (AUTHOR), Prabakar, Narmadha Lakshmi2 (AUTHOR), Senguttuvan, Thirumaran1 (AUTHOR), Bhaskar, Adhin3 (AUTHOR), Jagannathan, Muthukumaran4 (AUTHOR), Sivaraman, Ravi5 (AUTHOR), Ramasamy, Jayalakshmi2 (AUTHOR), Chinnaiyan, Ponnuraja3 (AUTHOR), Arumugam, Vijayalakshmi6 (AUTHOR), Getrude, Banumathy7 (AUTHOR), Sakthivel, Gautham2 (AUTHOR), Srinivasalu, Vignes Anand1 (AUTHOR), Rajendran, Dhanalakshmi1,8 (AUTHOR), Nadukkandiyil, Arunjith2 (AUTHOR), Ravi, Vaishnavi2 (AUTHOR), Hifzour Rahamane, Sadiqa Nasreen2 (AUTHOR), Athur Paramasivam, Nirmal2 (AUTHOR), Manoharan, Tamizhselvan3 (AUTHOR), Theyagarajan, Maheshwari1 (AUTHOR)
Publikováno v:
PLoS ONE. 2/3/2022, Vol. 17 Issue 2, p1-16. 16p.
Autor:
Gopalan, Narendran1 (AUTHOR) gopalannaren@yahoo.co.in, Srinivasalu, Vignes Anand1 (AUTHOR), Chinnayan, Ponnuraja1 (AUTHOR), Velayutham, Banurekha1 (AUTHOR), Bhaskar, Adhin1 (AUTHOR), Santhanakrishnan, Ramesh1 (AUTHOR), Senguttuvan, Thirumaran1 (AUTHOR), Rathinam, Sridhar2 (AUTHOR), Ayyamperumal, Mahilmaran3 (AUTHOR), Satagopan, Kumar2 (AUTHOR), Rajendran, Dhanalakshmi1 (AUTHOR), Manoharan, Tamizhselvan1 (AUTHOR), Lakshmanan, Sekar1 (AUTHOR), Paramasivam, Paulkumaran1 (AUTHOR), Angamuthu, Dhanalakshmi1 (AUTHOR), Ganesan, Mangalambal1 (AUTHOR), Easudoss Arockia, John Washington1 (AUTHOR), Venkatesan, Ramesh Babu1 (AUTHOR), Lakshmipathy, Venkatesan1 (AUTHOR), Shanmugham, Shivakumar1 (AUTHOR)
Publikováno v:
PLoS ONE. 9/20/2021, Vol. 16 Issue 9, p1-15. 15p.
Autor:
Laura Rosu, Jason J Madan, Ewan M Tomeny, Malaisamy Muniyandi, Jasper Nidoi, Mamo Girma, Valentina Vilc, Priyanka Bindroo, Rajdeep Dhandhukiya, Adamu K Bayissa, Daniel Meressa, Gopalan Narendran, Rajesh Solanki, Anuj K Bhatnagar, Elena Tudor, Bruce Kirenga, Sarah K Meredith, Andrew J Nunn, Gay Bronson, I D Rusen, S Bertel Squire, Eve Worrall, Saleem Ahmad, Sofia Alexandru, Katharine Bellenger, Tolera G. Bulga, Claire Cook, Valeriu Crudu, Bennet Deborah, Wendy Dodds, Belay A. Gebreegziabher, Ruth L. Goodall, Pritti Gupta, Meera Gurumurthy, Ivor Langley, Joanitah Nalunjogi, Saleem Khan, Saravanan Krishnan, Shravan Kumar, Maia Lesosky, Mariana Macari, Mukesh Makwana, Brendan Murphy, Ramesh P. Murugesan, Vanita Patel, Irina Pirlog, Mary Rauchenberger, Karen Sanders, Ramesh Singh, Sangeetha Subramani, Mekonnen Teferi, Netsanet A. Tegegn, Arun Babu Velmurugan, Johanna Whitney
Publikováno v:
The Lancet. Global health.
The STREAM stage 2 trial assessed two bedaquiline-containing regimens for rifampicin-resistant tuberculosis: a 9-month all-oral regimen and a 6-month regimen containing an injectable drug for the first 2 months. We did a within-trial economic evaluat